Transcode therapeutics stock.

Feb 18, 2023 · Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like they did in the case of TransCode Therapeutics, Inc. (NASDAQ:RNAZ), that sends ... 26 thg 9, 2023 ... Use of technology ... TransCode Therapeutics (NASDAQ:RNAZ) stock has seen a wild 24 hours of trading as the Boston headquartered nano-cap drug ...BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. RNAZ (the “Company”), an RNA oncology company committed to more effectively treating …--TransCode Therapeutics ... it has entered into a definitive securities purchase agreement for the purchase and sale of 5,000,000 shares of common stock at a purchase price of $0.242 per share of ...

BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) (the "Company"), an RNA oncology company committed to …Jul-08-21 06:34PM. TransCode Therapeutics, Inc. Announces Pricing of Initial Public Offering. (Business Wire) TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in ...

TransCode Therapeutics ( NASDAQ: RNAZ) said that it has entered into a definitive securities purchase agreement for the purchase and sale of 5,000,000 shares of common stock at a purchase price of ...

Oct 27, 2023 · BOSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA ... TransCode Therapeutics (NASDAQ:RNAZ) said that it has entered into a definitive securities purchase agreement for the purchase and sale of 5,000,000 shares of common stock at a purchase price of ...Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like they did in the case of TransCode Therapeutics, Inc. (NASDAQ:RNAZ), that sends ...Oct 30, 2023 · BOSTON, Oct. 30, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (the “Company”), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that it is withdrawing the underwritten public offering of its common stock. This reflects the Company’s belief that current ... Therapeutic counseling is a psychological service that focuses on helping individuals learn skills and techniques to facilitate coping make improvements in their own lives. Therapeutic counseling ultimately seeks to show clients how their t...

BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the commencement of an underwritten public offering of shares of its common stock. In addition, the Company expects to grant …

If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...

TransCode Therapeutics Announces Closing of $8.5 Million Public Offering. BOSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the closing of its previously …Great news for TransCode Therapeutics, Inc. (NASDAQ:RNAZ): Insiders acquired stock in large numbers last year. Usually, when one insider buys stock, it might not be a …TSLA Tesla, Inc. Common Stock $230.05 +0.01 BETR Better Home & Finance Holding Company Class A Common Stock $1.56 +0.41 +35.65% Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the...A. While ratings are subjective and will change, the latest TransCode Therapeutics ( RNAZ) rating was a reiterated with a price target of $0.00 to $3.00. The current price TransCode Therapeutics ...If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.

The company's lead therapeutic candidate includes TTX-MC138. TransCode Therapeutics is based in BOSTON. Stock Name, Country, Market Cap, PE Ratio. Zoetis (ZTS) ...TransCode Therapeutics Withdraws Public Offering October 27, 2023 Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The …The 1-for-20 reverse stock split will automatically convert 20 current shares of TransCode’s common stock into one new share of common stock. No fractional shares will be issued in connection ...TransCode Therapeutics ( NASDAQ: RNAZ) said that it has entered into a definitive securities purchase agreement for the purchase and sale of 5,000,000 shares of common stock at a purchase price of ...BOSTON, Nov. 30, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a definitive securities purchase agreement for the purchase and sale of 5,000,000 shares of …Overview News TransCode Therapeutics Inc. No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-19.57 Market Cap $4.82 M Shares …Nov 14, 2023 · TransCode Therapeutics, Inc. BOSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA ...

Find the latest historical data for TransCode Therapeutics, Inc. Common Stock (RNAZ) at Nasdaq.com.

TransCode Therapeutics ( NASDAQ: RNAZ) Thursday announced the commencement of an underwritten public offering of shares of its common stock. In addition, the company said it expects to grant the ...TransCode Therapeutics (NASDAQ:RNAZ) on Monday said it is withdrawing the underwritten public offering of its common stock."This reflects the company’s belief that current market conditions were ...The shares of common stock described above were offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-268764) previously filed with the Securities and ...BOSTON, Dec. 04, 2023 -- TransCode Therapeutics, Inc. , an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has closed its...Our Pipeline. TransCode Therapeutics has created a platform of therapeutic candidates with the objective of improving cancer patient outcomes. Our lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has been shown to be responsible for the majority of all cancer deaths annually. More on TTX-MC138.TransCode Therapeutics, Inc.: TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules 3 GlobeNewswire (USA)Nov 9, 2022 · Corporate Profile. TransCode Therapeutics is an emerging RNA oncology company committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics. TransCode’s proprietary platform, TTX, repurposes an iron oxide nanoparticle that has been extensively used for imaging to solve for RNA delivery in oncology. Stock analysis for TransCode Therapeutics Inc (RNAZ:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Dec 7, 2022 · TransCode Therapeutics (NASDAQ: RNAZ) stock is rallying higher on Wednesday after the company withdrew plans for a secondary offering. According to the company, it won’t pursue a plan to sell 12 ...

Insider Activity at TransCode Therapeutics. In other TransCode Therapeutics news, CFO Thomas A. Fitzgerald acquired 49,350 shares of the company’s stock in a transaction that occurred on Thursday, September 28th. The stock was bought at an average price of $0.51 per share, with a total value of $25,168.50.

TransCode Therapeutics, Inc. 0.3599. +0.0338. +10.36%. BOSTON, Oct. 30, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (the “Company”), the RNA oncology company committed ...

Nov 17, 2023 · Transcode Therapeutics Inc’s trailing 12-month revenue is $0.0 million with a % profit margin. Year-over-year quarterly sales growth most recently was %. Analysts expect adjusted earnings to reach $-5.570 per share for the current fiscal year. Transcode Therapeutics Inc does not currently pay a dividend. Transcode Therapeutics Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. ... TransCode Therapeutics is an emerging RNA oncology company. Its platform of investigational drug candidates is dedicated to improving patient outcomes encompassing a variety of tumor types. The ...TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating …TransCode Therapeutics stock is dropping alongside public offering plans.; The company hasn’t revealed the terms of the public offering just yet. That means traders still don’t know how many ...TSLA Tesla, Inc. Common Stock $230.05 +0.01 BETR Better Home & Finance Holding Company Class A Common Stock $1.56 +0.41 +35.65% Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the... TransCode Therapeutics Market Cap: 697.84K, Enterprise value: N/A, P/E: -0.34, PEG ratio: N/A, EPS: -6.95, Revenue: N/A, EBITDA: -18.29M, Income: -31.18M, ...Certain Stock Options of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-NOV-2023. Nov. 23: CI TransCode Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 Nov. 14: CI Further Supports TTX-MC138 Application in Brain CancerBOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively ...TRANSCODE THERAPEUTICS, INC. - Home Delivering a Cancer-Free Future TransCode Therapeutics: A Clinical-Stage Oncology Company Focused on Treating Metastatic …TransCode’s Chief Technology Officer and co-founder, Dr. Zdravka Medarova, said, “TTX-MC138 is a first-in-class therapeutic candidate against cancer, not only because of its molecular ...BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. RNAZ (the “Company”), an RNA oncology company committed to more effectively treating …Traders immediately bid up the RNAZ stock price this morning. It is truly a monumental day for TransCode Therapeutics (NASDAQ: RNAZ) stock. That’s because the company just disclosed the ...

TransCode Therapeutics, Inc. (RNAZ) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 0.2190 -0.0270 (-10.98%) At close: 04:00PM EST 0.2210 +0.00 (+0.91%) After hours: 07:59PM...TransCode Therapeutics Withdraws Public Offering October 27, 2023 Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The …TransCode Therapeutics ( NASDAQ: RNAZ) said that it has entered into a definitive securities purchase agreement for the purchase and sale of 5,000,000 shares of common stock at a purchase price of ...TransCode expects that its cash of approximately $5.0 million as of December 31, 2022, together with approximately $1.3M in net proceeds received from the sale of common stock in its February 2023 registered direct offering and $871 thousand of additional funding expected in the second quarter of 2023 for the third year of its SBIR award will ...Instagram:https://instagram. atlanta braves stocks2009 lincoln penniesis msft a good stock to buygold mining stocks list BOSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported ...TransCode Therapeutics, Inc. BOSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA ... wyshbox reviewsmysmartmove.com reviews Complete TransCode Therapeutics Inc. stock information by Barron's. View real-time RNAZ stock price and news, along with industry-best analysis. 1000 dollar bills for sale Oct 26, 2023 · BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today ... Oct 26, 2023 · TransCode Therapeutics Announces Public Offering of Common Stock. October 26, 2023. PDF Version. BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the commencement of an ... UNITED STATES . SECURITIES AND EXCHANGE COMMISSION . Washington, D.C. 20549 FORM 8-K. CURRENT REPORT . Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934